Top

Published in:

01-01-2009 | REVIEW

Innate immunity and myocardial adaptation to ischemia

Authors: Hanne Støre Valeur, Guro Valen

Published in: Basic Research in Cardiology | Issue 1/2009

Abstract

Myocardial adaptation to ischemia in the form of ischemic preconditioning is clinically attractive, but not directly usable until molecular mimics are discovered. A growing body of evidence indicates that events underlying myocardial adaptation to ischemia may either involve, or be parallel to, signaling of the innate immune response. Preconditioning-like protection of the heart can be evoked through giving cytokines or fragments of bacterial walls. A possible role for cytokines, toll-like receptors, and nuclear factor kappa B for evoking ischemic preconditioning are discussed. Through stimulating innate immunity, there is potential to bring preconditioning into the clinics in a reasonable time frame. The possibility that the underlying protective response may involve adaptive immunity through danger signaling is briefly reviewed.

Akira S, Takeda K (2004) Toll-like receptor signaling. Nat Rev Immunol 4:499–511PubMedCrossRef

Akira S, Takeda K, Kaisho T (2001) Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2:675–680PubMedCrossRef

Aukrust P, Damås JK, Gullestad L (2003) Immunomodulating therapy: new treatment modality in congestive heart failure. Congest Heart Fail 9:64–69PubMedCrossRef

Belesjorow S, Bolle I, Duschin A, Heusch G, Schulz R (2003) TNF-α antibodies are as effective as ischemic preconditioning in reducing infarct size in rabbits. Am J Physiol 284:H927–H930

Bigdeli MR, Khoshbaten A (2008) In vivo preconditioning with normobaric hyperoxia induces ischemic tolerance partly by triggering tumor necrosis factor a-converting enzyme/tumor necrosis factor-a/nuclear factor kappa B. Neuroscience 153:671–678PubMedCrossRef

Boyd JH, Mathur S, Wang Y, Bateman RM, Walley KR (2006) Toll-like receptor stimulation in cardiomyoctes decreases contractility and initiates an NF-kappaB dependent inflammatory response. Cardiovasc Res 72:384–393PubMedCrossRef

Brown JM, Grosso MA, Terada LS, Whitman GJ, Banerjee A, White CW, Harken AH, Repine JE (1989) Endotoxin pretreatment increases endogenous myocardial catalase activity and decreases ischemia-reperfusion injury of isolated rat hearts. Proc Natl Acad Sci 86:2516–2520PubMedCrossRef

Chandrasekar B, Freeman GL (1997) Induction of nuclear factor kappaB and activation protein 1 in postischemic myocardium. FEBS Lett 401:30–34PubMedCrossRef

Chao W, Shen Y, Zhu X, Zhao H, Novikov M, Schmidt U, Rosenzweig A (2005) Lipopolysaccharide improve cardiomyocyte survival and function after serum deprivation. J Biol Chem 280:21997–22005PubMedCrossRef

10.

Chong AJ, Shimamoto A, Hampton CR, Takayama H, Spring DJ, Rothnie CL, Yada M, Pohlman TH, Verrier ED (2004) Toll-like receptor 4 mediates ischemia/reperfusion injury of the heart. J Thorac Cardiovasc Surg 128:170–179PubMedCrossRef

11.

Dana A, Jonassen AK, Yamashita N, Yellon DM (2000) Adenosine A(1) receptor activation induces delayed preconditioning in rats mediated by manganese superoxide dismutase. Circulation 101:2841–2848PubMed

12.

Dawn B, Xuan YT, Guo Y, Rezazadeh A, Stein AB, Hunt G, Wu WJ, Tan W, Bolli R (2004) IL-6 plays an obligatory role in late preconditioning via JAK-STAT signaling and upregulation of iNOS and COX2. Cardiovasc Res 64:61–71PubMedCrossRef

13.

Deuchar GA, Opie LH, Lecour S (2007) TNFa is required to confer protection in an in vivo model of clasical ischemic preconditioning. Life Sci 80:1686–1691PubMedCrossRef

14.

Favre J, Musette P, Douin-Echinard V, Laude K, Henry JP, Arnal JF, Thuillez C, Richard V (2007) Toll-like receptors 2-deficient mice are protected against postischemic coronary endothelial dysfunction. Arterioscler Thromb Vasc Biol 27:1064–1071PubMedCrossRef

15.

Fischer P, Hilfiker-Kleiner D (2007) Survival pathways in hypertrophy and heart failure: the gp130-STAT3 axis. Basic Res Cardiol 102:279–297PubMedCrossRef

16.

Fox IS (1996) The immune system. In: Fox IS (ed) Human physiology. WC Brown Publishers, pp 424–456

17.

Frantz S, Ertl G, Bauersachs J (2007) Mechanisms of disease: toll-like receptors in cardiovascular disease. Nat Clin Pract Cardiovasc Med 4:444–454PubMedCrossRef

18.

Frantz S, Kelly RA, Bourcier T (2001) Role of TLR-2 in the activation of nuclear factor kappaB by oxidative stress in cardiac myocytes. J Biol Chem 276:5197–5203PubMedCrossRef

19.

Frantz S, Kobzik L, Kim YD, Fukazawa R, Medzhitov R, Lee RT, Kelly RA (1999) Toll4 (TLR4) expression in cardiac myocytes in normal and failing myocardium. J Clin Invest 104:271–280PubMedCrossRef

20.

Girn HRS, Ahilathirunayagam S, Mavor AID, Homer-Vanniasinkam S (2007) Reperfusion syndrome: cellular mechanisms of microvascular dysfunction and potential therapeutic strategies. Vasc Endovascular Surg 41:277–293PubMedCrossRef

21.

Gho BC, Schoemaker RG, van den Doel MA, Duncker DJ, Verdouw PD (1996) Myocardial protection by brief ischemia in noncardiac tissue. Circulation 94:2193–2200PubMed

22.

Guo Y, Jones WK, Xuan YT, Tang XL, Bao W, Wu WJ, Han H, Laubach VE, Ping P, Yang Z, Qiu Y, Bolli R (1999) The late phase of ischemic preconditioning is abrogated by targeted disruption of the inducible NO synthase gene. Proc Natl Acad Sci 96:11507–11512PubMedCrossRef

23.

Gurantz D, Yndestad A, Halvorsen B, Lunde OV, Omens JH, Ueland T, Aukrust P, Moore CD, Kjekshus J, Greenberg BH (2005) Etanercept or intravenous immunoglobulin attenuates expression of genes involved in post-myocardial infarction remodeling. Cardiovasc Res 67:106–115PubMedCrossRef

24.

Gurfinkel EP, de la Fuente RL (2004) Two-year follow-up of the FLU vaccination acute coronary syndromes (FLUVACS) registry. Texas Haert Inst J 31:28–32

25.

Gurfinkel EP, de la Fuente LR, Mendiz O, Mautner B (2004) Flu vaccination in acute coronary syndromes and planned percutaneous coronary interventions (FLUVACS) study. Eur Heart J 25:25–31PubMedCrossRef

26.

Hall G, Hasday JD, Rogers TB (2006) Regulating the regulator: NF-kappaB signaling in the heart. J Mol Cell Cardiol 41:580–591PubMedCrossRef

27.

Hayden MS, West AP, Ghosh S (2006) NF-kappaB and the immune response. Oncogene 25:6758–6780PubMedCrossRef

28.

Hiasa G, Hamada M, Ikeda S, Hiwada K (2001) Ischemic preconditioning and lipopolysaccharide attenuate nuclear factor kappa B activation and gene expression of inflammatory cytokines in the ischemia-reperfused myocardium. Jpn Circ J 65:984–990PubMedCrossRef

29.

Jones WK, Brown M, Wilhide M, He S, Ren X (2005) NF-kappaB in cardiovascular disease: diverse and specific effects of a “general” transcription factor? Cardiovasc Toxicol 5:183–202PubMedCrossRef

30.

Karikó K, Weissman D, Welsh FA (2004) Inhibition of toll-like receptor and cytokine signaling-a unifying theme in ischemic tolerance. J Cereb Blood Flow Metab 24:1288–1304PubMedCrossRef

31.

Kim SC, Ghanem A, Stapel H (2007) Toll-like receptor 4 deficiency: smaller infarcts, but no gain in function. BMC Physiol 7:5–9PubMedCrossRef

32.

Knuefermann P, Sakata Y, Baker JS, Huang CH, Sekiguchi K, Hardarson HS, Takeuchi O, Akira S, Vallejo JG (2004) Toll-like receptor 2 mediates Staphylococcus aureus-induced myocardial dysfunction and cytokine production in the heart. Circulation 110:3693–3698PubMedCrossRef

33.

Kurdi M, Booz GW (2007) Can the protective actions of JAK-STAT in the heart be exploited therapeutically? Parsing the regulation of interleukin-6-type cytokine signalling. J Cardiovasc Pharmacol 50:126–141PubMedCrossRef

34.

Labruto F, Yang J, Vaage J, Valen G (2005) Role of tumor necrosis factor alpha and its receptor 1 in preconditioning by hyperoxia. Basic Res Cardiol 100:198–207PubMedCrossRef

35.

Lacerda L, Smith RM, Opie LH, Lecour S (2006) TNFa-induced cytoprotection requires the production of free radicals within mitochondria in C₂C₁₂ myotubes. Life Sci 79:2194–2201PubMedCrossRef

36.

Lecour S, Suleman N, Deuchar GA, Somers S, Lacerda L, Huisamen B, Opie LH (2005) Pharmacological preconditioning with tumor necrosis factor 1 alpha activates signal transducer and activator of transcription-3 without involving classic prosurvival kinases. Circulation 112:3911–3118PubMedCrossRef

37.

Li C, Browder W, Kao RL (1999) Early activation of transcription factor NF-kappaB during ischemia in perfused rat heart. Am J Physiol 276:H543–H552PubMed

38.

Li C, Kao RL, Ha T, Kelley J, Browder IW, Williams DL (2001) Early activation of IKKbeta during in vivo myocardial ischemia. Am J Physiol 280:H1264–H1271

39.

Li G, Labruto F, Sirsjö A, Chen F, Vaage J, Valen G (2004) Myocardial protection by remote preconditioning: the role of nuclear factor kappa B p105 and inducible nitric oxide synthase. Eur J Cardiothorac Surg 26:968–973PubMedCrossRef

40.

Liem DA, Honda HM, Zhang J, Woo D, Ping P (2007) Past and present course of cardioprotection against ischemia-reperfusion injury. J Appl Physiol 103:2129–2136PubMedCrossRef

41.

Ma S, Xiang J, Wu J, Hu B (2003) Effects of lipoteichoic acid induced delayed preconditioning on ischemia-reperfusion injury in isolated rat hearts. Huazhong Univ Sci Technol Med Sci 23:230–233

42.

Matzinger P (2002) The danger model: a renewed sense of self. Science 296:301–305PubMedCrossRef

43.

Maulik N, Sato M, Price BD, Das DK (1998) An essential role of NFkappaB in tyrosine kinase signaling of p38 MAP kinase regulation of myocardial adaptation to ischemia. FEBS Lett 429:365–369PubMedCrossRef

44.

Medzhitov R (2001) Toll-like receptors and innate immunity. Nat Rev Immunol 1:135–145PubMedCrossRef

45.

Meyers DG (2003) Myocardial infarction, stroke, and sudden cardiac death may be prevented by influenza vaccination. Curr Atheroscler Rep 5:146–149PubMedCrossRef

46.

Miller EJ, Li J, Leng L, McDonald C, Atsumi T, Bucala R, Young LH (2008) Macrophage migration inhibitory factor stimulates AMP-activated protein kinas in the ischemic heart. Nature 451:578–583PubMedCrossRef

47.

Mitchell JA, Paul-Clarke MJ, Clarke GW, McMaster SM, Cartwright N (2007) Critical role of toll-like receptors and nucleotide oligomerization domain in the regulation of health and disease. J Endocrinol 193:323–330PubMedCrossRef

48.

Morand EF (2005) New therapeutic target in inflammatory disease: macrophage migration inhibitory factor. Intern Med J 35:419–426PubMedCrossRef

49.

Morgan EN, Boyle EM Jr, Yun W, Griscavage-Ennis JM, Farr AL, Canty TG Jr, Pohlman TH, Verrier ED (1999) An essential role for NF-kappaB in the cardioadaptive response to ischemia. Ann Thorac Surg 68:377–382PubMedCrossRef

50.

Murry CE, Jennings RB, Reimer KA (1986) Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 74:1124–1136PubMed

51.

Naghavi M, Barlas Z, Siadaty S, Naguib S, Madjid M, Casscells W (2000) Association of influenza vaccination and reduced risk of recurrent myocardial infarction. Circulation 102:3039–3045PubMed

52.

Neckar J, Ostadal B, Kolar F (2004) Myocardial infarct size limiting effect of chronic hypoxia persists for five weeks of normoxic recovery. Physiol Res 53:621–628PubMed

53.

Nemeto S, Vallejo JG, Knuefermann P, Misra A, Defreitas G, Carabello BA, Mann DL (2002) Escherichia coli LPS-induced LV dysfunction: role of toll-like receptor 4 in the adult heart. Am J Physiol 282:H2361–H2323

54.

Nichol KL, Nordin J, Mullooly J, Lask R, Fillbrandt K, Iwane M (2003) Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly. New Engl J Med 348:1322–1332PubMedCrossRef

55.

Nilsson J, Hansson GK, Shah PK (2005) Immunomodulation of atherosclerosis: implications for vaccine development. AT&VB 25:18–28

56.

Otani H (2008) Ischemic preconditioning: from molecular mechanisms to therapeutic opportunities. Antiox Redox Signal 10:207–247CrossRef

57.

Oxman T, Arad M, Klein R, Avazov N, Rabinowitz B (1997) Limb ischemia preconditions the heart against reperfusion tachyarrhythmia. Am J Physiol 273:H1707–H1712PubMed

58.

Oyama J, Blais C, Liu X, Pu M, Kobzik L, Kelley RA, Bourcier T (2004) Reduced myocardial ischemia-reperfusion injury in toll-like receptor 4-deficient mice. Circulation 109:784–789PubMedCrossRef

59.

Sack MN (2002) Tumor necrosis factor-α in cardiovascular biology and the potential role for anti-tumor necrosis factor-α therapy in heart disease. Pharmacol Ther 94:123–135PubMedCrossRef

60.

Scheibner KA, Lutz MA, Boodoo S, Fenton MJ, Powell JD, Horton MR (2006) Hyaluronan fragments act as an endogenous danger signal by engaging TLR2. J Immunol 177:1272–1281PubMed

61.

Schulz R, Aker S, Belosjorov S, Heusch G (2004) TNFα in ischemia/reperfusion injury and heart failure. Basic Res Cardiol 99:8–11PubMedCrossRef

62.

Shi Y, Evans JE, Rode KL (2003) Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 425:516–521PubMedCrossRef

63.

Shinmura K, Tang XL, Wang Y, Xuan YT, Liu SQ, Takano H, Bhatnagar A, Bolli R (2000) Cyclooxygenase-2 mediates the cardioprotective effects of the late phase of ischemic preconditioning in conscious rabbits. Proc Natl Acad Sci 97:10197–10202PubMedCrossRef

64.

Shishido T, Nozaki N, Yamaguchi S, Shibata Y, Nitobe J, Miyamoto T, Takahashi H, Arimoto T, Maeda K, Yamakawa M, Takeuchi O, Akira S, Takeishi Y, Kubota I (2003) Toll-like receptor-2 modulates ventricular remodeling after myocardial infarction. Circulation 108:2905–2910PubMedCrossRef

65.

Smart N, Mojet MH, Latchman DS, Marber MS, Duchen MR, Heads RJ (2006) IL-6 induces PI 3-kinase and nitric oxide-dependent protection and preserves mitochondrial function in cardiomyocytes. Cardiovasc Res 69:164–177PubMedCrossRef

66.

Smith RM, Suleman N, McCarthy J, Sack MN (2002) Classic ischemic but not pharmacologic preconditioning is abrogated following genetic ablation of the TNFα gene. Cardiovasc Res 55:553–560PubMedCrossRef

67.

Song W, Furman BL, Parratt JR (1998) Monophosphoryl lipid A reduces both arrhythmia severity and infarct size in a rat model of ischaemia. Eur J Pharmacol 345:285–287PubMedCrossRef

68.

Suleman N, Somers S, Smith R, Opie LH, Lecour S (2008) Dual activation of STAT-3 and Akt is required during the trigger phase of ischemic preconditioning. Cardiovasc Res 79:127–133PubMedCrossRef

69.

Takaoka A, Nakae I, Mitsunami K, Yabe T, Morikawa S, Inubushi T, Kinoshita M (1999) Renal ischemia/reperfusion remotely improves myocardial energy metabolism during myocardial ischemia via adenosine receptors in rabbits: effects of remote preconditioning. J Am Coll Cardiol 100:559–563

70.

Takeda K, Akira S (2004) TLR signaling pathways. Semin Immunol 16:3–9PubMedCrossRef

71.

Teoh N, Field J, Farrell G (2006) Interleukin 6 is a key mediator of the hepatoprotective and pro-proliferative effects of ischemic preconditioning in mice. J Hepatol 45:20–27PubMedCrossRef

72.

Tissier R, Berdeaux A, Ghaleh B, Couvreur N, Krieg T, Cohen MV, Downey J (2008) Making the heart resistant to infarction: how can we further decrease infarct size? Front Biosci 13:284–301PubMedCrossRef

73.

Tsan MF, Gao B (2004) Endogenous ligands of toll-like receptors. J Leukoc Biol 76:514–519PubMedCrossRef

74.

Tähepõld P, Vaage J, Starkopf J, Valen G (2003) Hyperoxia elicits myocardial protection through a nuclear factor kappaB-dependent mechanism in the rat heart. J Thorac Cardiovasc Surg 125:650–660PubMedCrossRef

75.

Valen G, Hansson GK, Dumitrescu A, Vaage J (2000) Unstable angina activates myocardial heat shock protein 72, endothelial nitric oxide synthase, and transcription factors NFkB and AP-1. Cardiovasc Res 47:49–56PubMedCrossRef

76.

Valen G, Yan ZQ, Hansson GK (2001) Nuclear factor kappa-B and the heart. J Am Coll Cardiol 38:307–314PubMedCrossRef

77.

Wallin RP, Lundqvist A, Moré SH, von Bonin A, Kiessling R, Ljunggren HG (2002) Heat-shock proteins as activators of the innate immune system. Trends Immunol 23:130–135PubMedCrossRef

78.

Wang Y, Yin BL, Liu S, Xue S (2007) Cardioprotective effect by tumor necrosis factor-a and interleukin-6 through late preconditoning in unstable angina patients. Arch Med Res 38:80–85PubMedCrossRef

79.

Xuan YT, Tang XL, Banerjee S, Takano H, Li RC, Han H, Qiu Y, Li JJ, Bolli R (1999) Nuclear factor-kappaB plays an essential role in the late phase of ischemic preconditioning in conscious rabbits. Circ Res 84:1095–1109PubMed

80.

Yan ZQ, Hansson GK (2007) Innate immunity, macrophage activation, and atherosclerosis. Immunol Rev 219:187–203PubMedCrossRef

81.

Yellon DK, Hausenloy DJ (2007) Myocardial reperfusion injury. N Engl J Med 357:1121–1123PubMedCrossRef

82.

Zacharowski K, Frank S, Otto M, Chatterjee PK, Cuzzocrea S, Hafner G, Pfeilschifter J, Thiemermann C (2000) Lipoteichoic acid induces delayed protection in the rat heart: a comparison with endotoxin. Arterioscler Thromb Vasc Biol 20:1521–1528PubMed

83.

Zhang C (2008) The role of inflammatory cytokines in endothelial dysfunction. Basic Res Cardiol 103:398–406PubMedCrossRef

84.

Zhao ZQ, Vinten-Johansen J (2006) Postconditioning: reduction of reperfusion-induced injury. Cardiovasc Res 70:200–211PubMedCrossRef

Title: Innate immunity and myocardial adaptation to ischemia
Authors: Hanne Støre Valeur
Guro Valen
Publication date: 01-01-2009
Publisher: D. Steinkopff-Verlag
Published in: Basic Research in Cardiology / Issue 1/2009
Print ISSN: 0300-8428
Electronic ISSN: 1435-1803
DOI: https://doi.org/10.1007/s00395-008-0756-6

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The STEP trials

Springer Medicine

Innate immunity and myocardial adaptation to ischemia

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2009

Thyroid hormone improves postischaemic recovery of function while limiting apoptosis: a new therapeutic approach to support hemodynamics in the setting of ischaemia-reperfusion?

Tribute to Wolfgang Schaper on the occasion of his 75th birthday

Activation of sphingosine kinase by muscarinic receptors enhances NO-mediated and attenuates EDHF-mediated vasorelaxation

Propylthiouracil, independent of its antithyroid effect, decreases VSMC collagen expression

On the occasion of Wolfgang Schaper’s 75th birthday

Identification of mutational hot spots in LMNA encoding lamin A/C in patients with familial dilated cardiomyopathy

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page